Abstract | Programmed cell death (PCD) is a key process in the regulation of immune cell development and peripheral immune homeostasis. Caspase-dependent apoptosis, as well as a number of alternative cell death mechanisms, account for immune cell PCD induced by cell-intrinsic and extrinsic pathways. In animal models, compelling evidence has emerged that genetic defects in PCD can result in autoimmune disease. Autoimmune disease can arise from single-gene mutations that affect PCD, and defective PCD has been observed in some tissues and cells from patients with rheumatic disease. Selectively inducing PCD in autoreactive B and T cells is very attractive as a therapeutic strategy because it offers the possibility of permanent elimination of these pathogenic cell subsets. In addition, the anti-inflammatory effects of apoptotic cells may add to the therapeutic benefit of induced PCD. Immune cell subsets vary widely in their sensitivity to specific inducers of cell death, and understanding these differences is key to predicting the outcome of inducing apoptosis for therapeutic means. Here, we review approaches that have been used to induce PCD in the treatment of autoimmune disease, and describe the prospects of bringing these experimental strategies into clinical practice.
Introduction
Multicellular organisms use apoptosis, or programmed cell death (PCD), to eliminate excess cells during develop ment and to maintain tissue homeostasis. PCD occurs through a number of different mechanisms, the best understood of which is caspase-dependent apoptosis, which can be triggered by extrinsic or intrinsic stimuli. In general, apoptotic cells do not trigger inflammation; indeed, they might actively suppress it. Utilizing this mechanism to eliminate autoreactive lymphocytes in autoimmune disease is an attractive strategy for immunotherapy because of the potentially long-lasting effects of the physical removal of pathogenic cells. In this Review, we describe the major mechanisms of PCD, their disruption in immunological and rheumatic diseases, and the prospects of harnessing PCD for therapeutic purposes.
Mechanisms of PCD and the immune system
Apoptosis can be triggered by extrinsic signals transduced through cell-surface receptors (extrinsic apoptosis pathway), or by intrinsic pathways induced by DNA damage or other cellular stresses. These pathways are in tegrated by mitochondria and converge with the activation of caspases, a family of cysteine proteases that cleave a multitude of cellular substrates. These cleaved substrates in turn produce the cellular changes associated with apoptosis, such as DNA fragmentation, dismantling of the cytoskeleton and nuclear envelope, and packaging of cellular contents into apoptotic blebs. Apoptotic cells also display specific surface markers, such as phosphatidylserine, that are recognized by phagocytic cells, usually leading to their rapid removal from circulation.
Extrinsic apoptosis pathways
In the immune system, the extrinsic cell death pathway is mediated principally by cytokines of the tumor necrosis factor (TNF) family, in particular Fas ligand (FasL; also known as CD178) and TNF-related apoptosis-inducing ligand (TRAIL; also known as CD253). Activated T cells can produce both TRAIL and FasL after stimulation through the T cell receptor (TCR). FasL is also reported to be constitutively expressed in some tissues associated with immune privilege, such as the eyes and the testes. 1, 2 Myeloid cells can produce TRAIL, particularly after stimulation by type I interferons or in response to viral infection. 3 Fas (also known as CD95) and the two functional receptors for TRAIL, death receptor 4 (DR4) and death receptor 5 (DR5), can efficiently induce apoptosis owing to a conserved 'death domain' located in the intracytoplasmic tail of these receptors. Fas and TRAIL receptor death domains interact with the death domain in the adapter protein FADD (Fas-associated protein with death domain). A related domain in FADD, termed the death effector domain (DED), recruits the cysteine protease caspase 8 to the receptor signaling complex.
Caspase 8 is part of the subfamily of cysteine proteases that cleave substrate proteins at aspartate residues. Caspases can be involved in both inflammatory and apoptotic signaling. 4 Caspase 8 is present in the cell as a pro-enzyme that requires aggregation and cleavage in a multimerized complex, consisting of ligated receptor (such as Fas, DR4 or DR5) and FADD, to become fully active. This multimerized complex is termed the death-inducing signaling complex (DIsC). 5, 6 c-FLIP (cellular FLICE-like inhibitory protein), an enzymatically in active homolog of caspase 8, is required in low amounts for processing of caspase 8 in the DIsC, but can block caspase 8 activation when present at higher concentrations. [7] [8] [9] The active fragments of caspase 8 assemble into a tetramer and dissociate from the receptor complex, enabling activation of downstream cytoplasmic 'effector' caspases 3, 6 and 7. 4 Effector caspases can cleave cellular substrates in order to execute the apoptotic program. In some cell types, large amounts of caspase 8 are produced by the receptor signaling complex that can directly cleave effector caspases, whereas in other cells, the caspase 8 generated by the DIsC requires amplification by the mitochondrial mechanisms shared with intrinsic cell death pathways (Figure 1) . 10, 11 Fas and TRAIL receptors are expressed on activated T cells; however, Fas-FasL interactions are principally responsible for eliminating chronically stimulated lympho cytes, which is important for maintaining peripheral immunological tolerance. [12] [13] [14] More recently, Fas has been shown to trigger nonapoptotic responses, such as increased migration, chiefly in myeloid cells. [14] [15] [16] TRAIL can induce rapid cell death of transformed tumor cells in vitro, but its physiological function is less clear. Experiments in mice with TRAIL or TRAIL-receptor deficiencies have indicated a role for this pathway in tumor surveillance and elimination of CD8 + T cells that have not received T-cell help from CD4 + T cells. 17, 18 Two other members of the TNF receptor superfamily, TNFR1 (TNF receptor 1) and death receptor 3 (DR3) interact with the adapter protein TRADD (TNFR1-associated death domain protein), which mediates the assembly of a primary membrane-bound signaling complex (termed complex I) containing TRAFs (TNF-receptor associated factors), inhibitor of apoptosis proteins IAP1 (also known as BIRC2) and IAP2 (also known as BIRC3), and RIPK1 (receptor-interacting protein kinase 1). This protein complex triggers proinflammatory cellular responses through nuclear factor-κB (NF-κB) and mitogenactivated protein kinase (MAPK) signaling. 19 Not until hours after receptor internalization and dissociation of TRADD from the receptor are FADD and caspase 8 recruited to this cytoplasmic signaling complex (termed complex II), 19 allowing the induction of apoptosis. The regulatory protein c-FLIP is synthesized in response to NF-κB activation, which is partially responsible for the protective functions of NF-κB. Thus, except in circumstances where NF-κB activation is blocked, stimulation of TNFR1 and DR3 usually results in cellular activation and synthesis of proinflammatory cytokines, and does not induce PCD.
other members of the TNF receptor family do not have a death domain, and cannot directly induce apoptosis; instead, they recruit TRAF proteins via peptide consensus sequences, triggering production of proinflammatory cytokines and promoting cell survival. However, these receptors can trigger cell death indirectly by modulating the availability of signaling proteins to apoptosis-inducing 20 Depletion of these proteins in the TNFR1 signaling complex enhances the apoptosisinducing ability of TNFR1. 21 such crosstalk might be harnessed for therapeutic purposes.
Intrinsic apoptosis pathways
Cell-intrinsic stimuli can trigger apoptosis through activation of caspases independently of cell-surface receptors ( Figure 1 ). Intrinsic stimuli include withdrawal of cytokines that support cell survival, or exposure to mutagens that result in DNA damage or hormones such as glucocorticoids. 22 ,23 sensors of DNA damage or hormone receptors relay apoptotic signals through the Bcl-2 family of proteins, which comprises proapoptotic and anti apoptotic members that are characterized by the presence of BH (Bcl-2 homology) domains. 24 The antiapoptotic proteins Bim, Bid, Noxa and Puma contain only BH3 domains, 25 whereas the proapoptotic Bcl-2 members Bax and Bak contain several different types of BH domains. Bid can be cleaved by active caspase 8 in the signaling complex of death receptors, resulting in a truncated protein (tBid). tBid translocates to the mito chondria where it induces conformational changes in other Bcl-2 family proteins, resulting in a rapid opening of channels in the mitochondrial outer membrane, referred to as mitochondrial outer membrane permeabiliza tion (MoMP). 26, 27 MoMP disrupts mitochondrial energy generation and releases cytochrome c into the cytoplasm, which is a key activator of the 'apoptosome' , a complex of caspase 9 and APAF1 (apoptotic protease activating factor 1).
The antiapoptotic Bcl-2 family members (such as Bcl-2, Bcl-xL and Mcl-1) contain multiple BH domains (BH1-4) that have a critical role in directly inhibiting proapoptotic Bcl-2 members through a conformational interaction. A second layer of regulation is mediated by IAP proteins such as XIAP (X-linked inhibitor of apoptosis protein; also known as BIRC4), which bind to and inhibit the active form of effector caspases. Molecules such as smac protein (also known as DIABLo homolog), which are also released from the mitochondria after MoMP, can inactivate IAP proteins, providing an additional feed-forward loop that reinforces caspase activation. 28 Together, these regulatory pathways result in a latent period, during which upstream signals, such as death receptor ligation, produce small amounts of caspase activity and activate BH3 proteins, followed by a very rapid onset (within 2-3 min) of apoptosis, with MoMP, release of cytochrome c, and activation of effector caspases occurring almost simultaneously ( Figure 1 ). 29 Apoptosis pathways and immune homeostasis Intrinsic and extrinsic apoptosis pathways come into play during different phases of the immune response. After the rapid proliferation of antigen-specific T cells that occurs during the first 4-7 days of an acute immune response, the reduction in the number of effector T cells is largely due to cytokine withdrawal via the intrinsic apoptotic pathway. once the T cell pool expands beyond the availability of interleukin (IL)-7 and IL-15, levels of Bcl-2 fall, levels of the proapoptotic BH3 protein Bim rise, and Bim-mediated apoptosis ensues. 30, 31 Fas contributes to the elimination of T cells only under conditions of chronic infection or repetitive stimulation by autoantigens. [32] [33] [34] Repeated TCR stimulation upregulates FasL, which induces apoptosis in Fas-bearing T cells through the process of re-stimulation-induced cell death (RICD). RICD leads to clonal deletion of these cells without affecting bystander T cells with different antigenic specificities. 35 This specificity occurs because TCR stimulation induces a 'competency to die' signal in addition to FasL synthesis. TCR signaling preferentially sensitizes re-stimulated T cells to undergo PCD in comparison to activated bystander T cells. Not all aspects of TCR signaling are necessary to sensitize T cells to Fasdependent apoptosis, but activation of Rac GTPasesmembers of the small G-protein signaling family that regulate actin polymerization and cytoskeletal remodeling-have been shown to be necessary. 36 one of the results of Rac activation is translocation of Fas to lipid raft microdomains, which increase the efficiency of Fas-induced apoptosis. 36, 37 How this type of cytoskeletal reorganization relates to changes that take place during the formation of an immune synapse between a T cell and an antigen-presenting cell (APC) is not known.
Caspase-independent cell death mechanisms
The use of caspase inhibitors and caspase-deficient mice has led to the identification of several mechanisms of caspase-independent cell death. 38 Necrosis and autophagic cell death are two such caspase-independent mechanisms. 39 Necrosis, previously considered to be an uncontrolled, catastrophic form of cell death, has been found, in some cases, to result from regulated signaling events. Necrosis arising from caspase inhibition during death receptor signaling is termed 'necroptosis' , Figure 1 | extrinsic and intrinsic apoptosis pathways. Induction of apoptosis by the extrinsic pathway depends on the FADD/caspase 8 DISC formed by the ligand-bound death receptor (Fas, TRAIL, or TNFR1). Active caspase 8 generated from an efficient DISC, which can be inhibited by high levels of c-FLIP , is sometimes sufficient to induce apoptosis via caspase 3 activation. However, crosstalk between extrinsic and intrinsic pathway can occur through Bid cleavage, which leads to activation of the proapoptotic BH3-containing Bcl-2 family proteins Bax and Bak, ultimately resulting in MOMP. The intrinsic apoptosis pathway depends on MOMP and apoptosome formation, resulting in caspase 3 activation and apoptosis. Intrinsic apoptosis is more closely regulated by the balance between the antiapoptotic and proapoptotic members of the Bcl-2 family of proteins (including Bcl-2, Bax and Bak), and the activity of inhibitors of apoptosis proteins. Irrespective of the initiating apoptosis stimuli, activation of caspase 3 indicates an irreversible final stage in the process of apoptosis. Abbreviations: APAF1, apoptotic protease-activating factor 1; DISC, death-inducing signaling complex; FADD, Fas-associated protein with death domain; c-FLIP, cellular FLICe-like inhibitory protein; FasL, Fas ligand; MOMP, mitochondrial outer membrane permeabilization; Smac, second mitochondria-derived activator of caspase; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TNFR1, tumor necrosis factor receptor 1; XIAP, X-linked inhibitor of apoptosis protein.
and is morphologically indistinguishable from necrosis. This 'backup' mechanism of cell death may constitute an immune defense mechanism against viruses, which often encode caspase inhibitors in their genome. Recent evidence has implicated RIPK1 and RIPK3, proteins that are also involved in TNFR1-induced NF-κB activation, in necroptosis. 40 small-molecule inhibitors of RIPK1, termed necrostatins, can block necroptosis in some cell types. 41 Autophagy, on the other hand, is a physiological response to nutrient deprivation in which intra cytoplasmic or ganelles are recycled in double-walled, membranebound vacuoles termed autophagosomes. Accumulation of these autophagic vacuoles has been observed in some cells undergoing cell death. Under these conditions, cell death can be blocked by inhibiting autophagy, suggesting that autophagy may be part of the mechanism of this type of cell death. 42 Autophagic cell death has been suggested to underlie the apoptosis that occurs when T cells are activated in the presence of caspase inhibitors or under conditions of FADD or caspase 8 deficiency. 43 These findings suggest that caspases might have a critical role in controlling lymphocyte survival at both ends of a spectrum: too little caspase activation triggers an autophagic death program, whereas high levels of caspase activation, such as after ligation of Fas, triggers apoptotic cell death.
Recognition and uptake of apoptotic cells
Apoptotic cells are usually rapidly phagocytosed by macrophages. The process of phagocyte recognition and engulfment depends on various recognition signals that are exhibited by the cell undergoing apoptosis. one of the classic recognition signals is the membrane lipid phosphatidylserine, which translocates from the inner to outer leaflet of the plasma membrane upon apoptosis. Phosphatidylserine can be recognized by specific receptors on phagocytes, but the efficiency of apoptotic cell recognition is increased by many other intermediary molecules that aid in the recognition of dying cells. 44 After ingesting apoptotic cells, macrophages downregulate the secretion of proinflammatory cytokines, such as TNF, IL-8 and IL-1β, and increase their production of anti-inflammatory mediators, such as transforming growth factor-β. 45 Dendritic cells, following uptake of apoptotic cells, increase production of transforming growth factor-β and induce naive T cells to differentiate into regulatory T cells. 46 Because of these responses, the uptake of apoptotic cells has generally been thought to suppress inflammation and promote adaptive immune tolerance.
The tolerogenic nature of apoptotic cell recognition and uptake is underscored by the autoimmunity that results from genetic defects in the mechanisms of recog nition and uptake of apoptotic cells. The classical complement component C1q is required for efficient apoptotic cell phagocytosis, and binds to the C1q receptor on phagocytes. C1q-knockout mice develop glomerulo nephritis, accumulate apoptotic bodies and exhibit increased mortality. 47 Humans with homozygous C1q deficiency also have a strong predisposition to the development of systemic lupus erythematosus (sLE). 48 Mice lacking other complement components, receptors in the AXL/TYRo3/MER family that indirectly recognize phosphatidyl serine through intermediary bridge molecules, or MFG-E8 (a bridging molecule in apoptotic cell recognition) also develop systemic autoimmunity. [49] [50] [51] Taken together, these findings suggest that coordinated recognition and uptake of apoptotic cells is an important part of immuno logical self-tolerance. 53 In humans, dominant-negative mutations in Fas or FasL cause the familial autosomal-dominant condition ALPs (autoimmune lympho proliferative syndrome), which bears a striking resemblance to Fas deficiency in mice. ALPs typically presents during childhood with chronic lymphadenopathy, hepatosplenomegaly and autoimmunity, most commonly manifested as auto immune hemolytic anemia or idiopathic thrombocytopenia purpura. DN T cells accumulate in the peripheral blood and, to an even greater extent, in the lymph nodes. [54] [55] [56] Mutations throughout the Fas protein have been documented in patients with ALPs, with the most frequent being mutations in the death domain that impair formation of the Fas signaling complex. Interestingly, patients with caspase 8 deficiency present with immunodeficiency rather than autoimmunity and have defects in lymphocyte activation, 57 perhaps due to the role of caspases in preventing autophagic cell death during lymphocyte activation, as discussed above.
Genetic diseases involving apoptosis

Immunologic disorders
The central role of the Fas-FasL system in maintaining peripheral tolerance is exemplified by the autoimmune syndromes that result from genetic defects in Fas or FasL. Mice harboring loss-of-function mutations in Fas (also known as
Rheumatic diseases
In sporadic rheumatic diseases, multiple genetic susceptibility loci interact with the environment to produce disease. Although no single genetic locus controls disease, a number of candidate genetic variants may influence cellular susceptibility to apoptosis. Phenotypic studies have found alterations in apoptosis or apoptotic cell uptake mechanisms in tissue samples from patients with rheumatic diseases. In rheumatoid arthritis (RA), the accumulation of inflammatory cells at sites of active disease could be due to increased cellular proliferation, reduced apoptosis, or both. Experiments using a number of different detection techniques have shown the presence of remarkably few apoptotic cells in the rheumatoid synovium. 58 Although peripheral monocytes express Fas and FasL and are highly sensitive to Fas apoptosis, synovial macrophages obtained from diseased joints show increased expression of c-FLIP and are resistant to apoptosis induced by Fas. A reduction in c-FLIP can restore Fas sensitivity, suggesting that decreasing the expression of c-FLIP through RNA interference of NF-κB activity may be a feasible therapeutic strategy to reduce macrophage numbers in RA. 59 Inhibition of NF-κB activity can also sensitize macrophages to undergo apoptosis in response to TNF, 60 suggesting therapeutic NF-κB inhibition as another strategy to subvert the effects of TNF in RA.
In sLE, alterations in the kinetics of cell death and uptake of apoptotic cells may alter the normal nonimmunogenic nature of apoptosis. T cells in sLE have been observed to undergo reduced apoptosis when stimulated through the TCR. 61 This may be due to alterations in TCR signaling proteins, including deficiency in the TCR zeta chain, which is known to be required for TCRinduced apoptosis. 62 However, T cells from patients with sLE have also been found to undergo accelerated spontaneous apoptosis. 63 some of these findings may be due to alterations in T cell subsets or activation status known to occur in sLE, rather than cell-intrinsic dif ferences in apoptotic signaling. Another line of evidence has revealed altered uptake of apoptotic cells as a possible pathogenic mechanism in sLE. Macrophages derived from sLE monocytes are impaired in their ability to ingest apoptotic material in vitro. 64 In vivo, lymph node biopsy samples from sLE patients with active disease contained multiple nonphagocytosed apoptotic cells in the germinal centers, whereas these were not present in samples from non-sLE control patients. 64 TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assays have demonstrated attachment of apoptotic material to follicular dendritic cells in sLE patients, ultimately allowing these antigens to be presented to T cells. [64] [65] [66] Accumulation of apoptotic cells may allow autoantigens that are normally eliminated through phagocytosis to become immunogenic, adding 'fuel to the fire' of autoimmunity in sLE and other autoimmune diseases. 67 
Therapeutic induction of PCD
Current therapies
A number of therapeutic agents already in use for rheumatic disease induce apoptosis as either all or part of their mode of action (Table 1) . Rituximab, a chimeric anti-CD20, B-cell-specific monoclonal antibody that was originally developed to treat B-cell malignancies, is approved for use in RA, and is also used in other B-celldependent autoimmune diseases, including pemphigus and sLE. Rituximab profoundly depletes circulating B cells through a number of mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and apoptosis. 68, 69 Blockade of IL-6 with tocilizumab, a mono clonal antibody against IL-6 receptor that was approved for the treatment of RA in the UsA in 2010, also acts as a pro apoptotic agent, as IL-6 protects against TCRmediated and Fas-induced apoptosis in a number of settings. [70] [71] [72] some studies have suggested that anti-TNF monoclonal antibodies (but not TNFR2-Fc fusion proteins such as etanercept) can acutely induce apoptosis in T cells and synovial macrophages that express surface TNF by similar mechanisms. 73 This may explain the superior efficacy of anti-TNF monoclonal antibodies over etanercept in diseases such as inflammatory bowel disease. [74] [75] [76] ADCC has been exploited by newer investigational agents to target specific populations of cells, such as an anti-lymphotoxin-α monoclonal antibody, which specifically depletes type 1 and type 17 helper T cells on the basis of their increased expression of surface lymphotoxin. 77 small-molecule therapeutics that are currently used in the management of rheumatic diseases may also exert some of their therapeutic effects through apoptosis. High-dose glucocorticoids induce apoptosis in eosinophils and lymphocytes. The mechanisms by which this occurs are complex, and probably involve repression of transcription factors that promote cellular survival, such as NF-κB, and activation of caspase-dependent apoptosis. 78 Among other mechanisms, methotrexate, a mainstay of therapy for RA, may act through induction of PCD: in vitro, methotrexate can induce apoptosis in 20-30% of activated T cells at concentrations compar able to peak plasma levels in patients receiving this agent for RA. 79, 80 The generation of reactive oxygen species and the loss of mitochondrial membrane potential have been implicated in methotrexate-induced cell death, and methotrexate has also been reported to potentiate Fas-induced apoptosis. 79, 80 some support for the idea that methotrexate may deplete activated T cells came from a study in which methotrexate was found to deplete a subset of activated CD4 + CD28 + T cells that accumulate in RA patients. 81 Cyclophosphamide can also induce apoptosis in activated T cells, 79 and some of its beneficial effects in sLE and vasculitides may stem from elimination of autoreactive lymphocytes.
Rational targeting of the intrinsic cell death pathway by manipulating the Bcl-2 family of proteins can induce apoptosis, and may be useful in the treatment of rheumatic diseases. oblimersen sodium, a phosphorothioate REvIEwS antisense oligonucleotide that targets Bcl-2, has shown modest beneficial effects on disease progression and survival in patients with chronic lymphocytic leu kemia and malignant melanoma. 82 ABT-737 and other smallmolecule drugs have been developed that mimic the action of BH3 peptides to bind and inactivate Bcl-2. These drugs can potently induce apoptosis in tumor cells, although phosphorylated Bcl-2 and other antiapoptotic Bcl-2 family proteins, such as Mcl-1, are resistant to the effects of ABT-737. [83] [84] [85] ABT-737 was recently shown to be efficacious in mouse models of arthritis and immune-complex nephritis, although significant depression of B and T cell responses were seen, suggesting that the use of this agent may result in some generalized immunosuppression. 86 targeting Fas and other death receptor pathways Because of its intrinsic capability to induce apoptosis, and the heightened sensitivity of re-stimulated T cells to Fas-induced apoptosis, engagement of the TNF receptor Fas could be an interesting therapeutic strategy with which to eliminate autoreactive T cells without knowing their antigenic specificity (Box 1). overexpression of the FADD adapter protein in cultured RA synoviocytes induced apoptosis in these cells, and, in a xenograft mouse model of proliferating rheumatoid synovium, ectopic expression of FADD through retroviral transduction lead to a significant reduction in the number of synoviocytes and mononuclear cells. 87 Decreased levels of c-FLIP, another molecule that regulates Fas signaling, has been shown to sensitize fibroblast-like synoviocytes from RA patients to Fas-induced apoptosis, and increase the susceptibility of T cells to TCR-induced apoptosis. 88, 89 Indirect targeting of Fas through its ligand is another plausible therapeutic mechanism. The forkhead transcription factor FoXo3a is an upstream inhibitor of FasL synthesis. FoXo3a-deficient mice are very resistant to inflammatory arthritis in the K/BxN serum transfer model of RA due to increased neutrophil apoptosis as a result of upregulated FasL synthesis. 90 Directly inducing apoptosis through Fas is another strategy for the elimination of potentially autoreactive cells. Use of anti-Fas monoclonal antibodies in vivo has been limited by acute and fatal hepatic failure observed in mice due to Fas-induced hepatocyte apoptosis. 91 This effect is partially dependent on Fc-receptor-mediated crosslinking of the anti-Fas antibodies. 92 This problem has been avoided in a number of experimental models by using FasL rather than anti-Fas antibody, and targeting specific cell populations for Fas-mediated apoptosis. Although crosslinking of FasL with a secondary antibody reproduced the liver toxicity incurred by anti-Fas monoclonal antibodies, an engineered hexameric version of FasL retains cytotoxic potential and does not induce fatal liver toxicity. 93, 94 Human hexameric FasL (APo010; TopoTarget, Copenhagen, Denmark) is currently in early-stage human trials as a cancer therapy. 95 A fusion protein containing FasL and a fibroblast activation protein (FAP)-specific single-chain antibody limited the induction of apoptosis to only those cells expressing FAP. This FasL-anti-FAP fusion protein inhibited the growth of a FAP-expressing tumor without the lethality seen with nonspecific Fas targeting. 96 Focusing FasL on tumor cells through a fusion protein combining FasL with a high-affinity antibody against the T-cell leukemia-associated antigen CD7 led to apoptosis of CD7-expressing cells, and moderate tumoricidal activity in CD7-expressing leukemic cells from patients with acute T-cell leukemia. 97 Delivery of FasL has had some success in treating animal models of arthritis. A T-lymphoma cell line transfected with the human FasL gene induced apoptosis in cultured synoviocytes from RA patients, and could also deplete synoviocytes and mononuclear cells in mice with human rheumatoid synovial xenografts. 98 Adenovirusbased delivery of FasL ameliorated joint pathology in a mouse collagen-induced arthritis model. 99 These studies suggest that treating inflammatory joint disease through sensitizing synovial cells to Fas-mediated apoptosis may be a viable therapeutic strategy, provided these effects can be spatially limited to the affected joints.
Improved understanding of the pathways that sensitize cells to apoptosis-inducing receptors has led to the development of therapeutic strategies to activate these Box 1 | Potential therapeutic strategies targeting the Fas/FasL apoptosis pathway
FADD overexpression
Adenovirus-mediated overexpression of FADD induces apoptosis in cultured synoviocytes. In an in vivo RA synovium xenograft model, in which human rheumatoid synovium was engrafted into SCID mice, local injection of the FADD adenoviral vector induced effective in vivo apoptosis of the human synoviocytes. 87 Inhibition of c-FlIP expression c-FLIP antisense oligonucleotide increased apoptosis of antigen-specific pathogenic CD8
+ T cells in a contact hypersensitivity mouse model system. c-FLIP expression was lowered by a direct skin application of a modified c-FLIP antisense oligonuceotide that facilitated antigen tolerance and reduced inflammation in the dermatitis model. 89 In fibroblast-like synoviocytes derived from RA patients, downmodulation of c-FLIP sensitized them to Fas-mediated apoptosis, indicating that c-FLIP regulation is a plausible target for autoimmune therapy. Liver toxicity induced by anti-Fas mAb is dependent on Fc-receptor-mediated antibody crosslinking and amplification by the proapoptotic BH3 protein Bid; therefore, forms of FasL lacking the Fc-domain were thought to be less toxic. However, a hexameric form of FasL is still toxic to hepatocytes in a Bidindependent fashion. 106 targeted Fasl fusion protein A construct consisting of the extracellular soluble fraction of FasL conjugated to a single-chain antibody fragment against FAP generates an active form of FasL that is cytotoxic only to FAP-expressing cells. Injection of this fusion protein into mice with transplanted FAP-positive cancer cells results in specific elimination of the transplanted cells without hepatic toxicity. 96 A similar strategy to target antigenspecific leukemia cells was performed using FasL fused to an anti-CD7 singlechain antibody fragment to target CD7 + cells derived from patients with T cell acute lymphoblastic leukemia. pathways and allow apoptosis to be triggered by endogenous ligands. The cytoplasmic apoptosis inhibitor XIAP restrains both extrinsic and intrinsic apoptosis pathways by binding to and inhibiting active effector caspases 3 and 7. Mimetics of the N-terminal peptide in the protein smac, which is released from mito chondria during apoptosis, can displace XIAP from effector caspase. smac mimetics or a reduction in XIAP levels sensitizes many cell lines to undergo apoptosis in response to TNF, TRAIL and FasL. 100,101 Decreased XIAP levels in mice achieved through treatment with smac mimetics or genetic deficiency also sensitizes hepatocytes to FasL-mediated apoptosis. In some tumor cell lines, smac mimetics were found to initiate an autocrine loop of TNF-TNFR1-mediated cell death by activating the alternative NF-κB pathway and increasing TNF production, but this has not been observed in primary cells. As many TNF family members are upregulated in several rheumatic diseases, converting inflammatory signals to apoptotic signals with agents such as smac mimetics may be a viable therapeutic strategy in this setting.
T-cell subsets vary in their sensitivity to Fas-induced apoptosis. 102, 103 signaling through the TCR sensitizes cells to Fas-induced apoptosis, as well as inducing transcription and secretion of FasL. Understanding the signaling pathways through which the TCR induces apoptosis may allow therapeutic manipulation to promote apoptosis of autoreactive lymphocytes. sensitivity to Fas-induced apoptosis can be induced by low-affinity peptides for the TCR that do not induce FasL or cytokine production, which suggests that this is mediated through distinct signaling pathways. 104 TCR-mediated sensitization to Fas-induced apoptosis requires translocation of Fas to lipid raft microdomains in a manner dependent on the Rac family of GTPases. 36, 37 T cells lacking the wiskottAldrich syndrome protein (wAsp), which mediates actin remodeling downstream of the TCR, have defective TCR-mediated apoptosis associated with reduced secretion of FasL. 105 This defect may be one factor predisposing patients with wiskott-Aldrich syndrome and wAsp-deficient mice to the development of systemic autoimmunity at high frequencies, in addition to the immunodeficiency associated with this syndrome. The therapeutic activation of these signaling pathways may be one strategy for sensitizing autoreactive T cells to undergo apoptosis even when the autoantigen is unknown, which is the case in many human diseases.
Conclusions
over the past two decades, there have been tremendous advances in our understanding of the basic mechanisms underlying PCD. It is now clear that there are multiple pathways that cells utilize to undergo PCD, with caspasedependent apoptosis being one of many. In autoimmune diseases such as sLE, apoptotic cells that are opsonized by autoantibodies may tend to become immunogenic. However, treatments such as high-dose glucocorticoids or cyclophosphamide that can induce apoptosis as part of their mechanism of action are more beneficial than they are harmful in sLE. Induction of cell death, therefore, may be a reasonable strategy for eliminating excess inflammatory and autoreactive immune cells in patients with rheumatic diseases. Improved understanding of the molecular mechanisms of PCD and the signaling pathways by which it is modulated will be important for identifying new therapeutic targets in rheumatic and inflammatory diseases. Harnessing the intrinsic ability of lymphocytes to undergo PCD has the potential to fulfill one of the long-sought goals in the therapy of autoimmune diseases: elimination of autoreactive cells with minimal generalized immunosuppression.
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